Climb Bio, Inc. CLYM Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $8.36M-71.2% | $35.69M-59.1% | $25.8M-82.3% | $22.68M-89.8% | $29.02M-72.4% | ||
| $101.21M+46.6% | $65.4M+2.7% | $61.1M+29.5% | $62.02M— | $69.04M— | ||
| $3.84M+73.1% | $4.77M+20.6% | $4.06M-4.6% | $2.68M-6.2% | $2.22M-47.1% | ||
| $113.4M+13.1% | $105.85M-31.7% | $90.96M-54.0% | $87.38M-61.3% | $100.28M-8.2% | ||
| $250K— | $288K+44.7% | $318K— | $314K— | —— | ||
| $447K-0.9% | $505K+3.1% | $562K+4,583% | $618K+2,843% | $451K+306% | ||
| $1.53M+577% | $1.53M+9,463% | $1.53M— | $1.37M— | $226K— | ||
| $152.37M-24.1% | $167.74M-22.8% | $182.3M-18.0% | $192.39M-14.9% | $200.74M+83.6% | ||
| $860K+10.7% | $2.27M+222% | $477K+63.9% | $946K+85.9% | $777K+814% | ||
| $2.95M-51.7% | $4.46M+9.6% | $4.24M+39.4% | $5.04M+70.7% | $6.1M+131% | ||
| $263K+69.7% | $256K+63.1% | $228K+293% | $222K+122% | $155K-31.1% | ||
| $4.07M-42.1% | $6.98M+41.6% | $4.95M+44.6% | $6.21M+65.9% | $7.04M+139% | ||
| $216K-32.3% | $285K-24.0% | $352K— | $417K— | $319K— | ||
| $4.29M-41.7% | $7.27M+37.0% | $5.3M+54.9% | $6.62M+77.0% | $7.36M+149% | ||
| $5K-28.6% | $5K-28.6% | $7K0.0% | $7K0.0% | $7K+133% | ||
| $451.37M+1.7% | $449.76M+1.8% | $448.74M+2.0% | $444.76M+2.3% | $443.75M+68.1% | ||
| -$303.45M-21.1% | -$289.73M-26.0% | -$272.21M-22.9% | -$259.32M-22.0% | -$250.66M-59.0% | ||
| $157K-45.1% | $435K+1,791% | $469K+133% | $318K— | $286K— | ||
| $148.09M-23.4% | $160.48M-24.3% | $177M-19.1% | $185.76M-16.4% | $193.39M+81.8% | ||
| $152.37M-24.1% | $167.74M-22.8% | $182.3M-18.0% | $192.39M-14.9% | $200.74M+83.6% | ||
| $101.21M+46.6% | $65.4M+2.7% | $61.1M+29.5% | $62.02M— | $69.04M— | ||
| $1.53M+577% | $1.53M+9,463% | $1.53M— | $1.37M— | $226K— | ||
| $447K-0.9% | $505K+3.1% | $562K+4,583% | $618K+2,843% | $451K+306% | ||
| $447K-0.9% | $505K+3.1% | $562K+4,583% | $618K+2,843% | $451K+306% | ||
| $1.53M+577% | $1.53M+9,463% | $1.53M— | $1.37M— | $226K— | ||
| $447K-0.9% | $505K+3.1% | $562K+4,583% | $618K+2,843% | $451K+306% | ||
| $1.53M+577% | $1.53M+9,463% | $1.53M— | $1.37M— | $226K— | ||
| $2.95M— | $4.46M+9.6% | $4.24M— | $5.04M— | —— | ||
| $479K+1.1% | $541K+1.7% | $580K+900% | $639K+539% | $474K+111% | ||
| $451.37M+1.7% | $449.76M+1.8% | $448.74M+2.0% | $444.76M+2.3% | $443.75M+68.1% | ||
| $5K-28.6% | $5K-28.6% | $7K0.0% | $7K0.0% | $7K+133% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Climb Bio, Inc.'s total assets?
- Climb Bio, Inc. (CLYM) holds $152.4M in total assets, down 24.1% year over year.
- How much debt does Climb Bio, Inc. have?
- Climb Bio, Inc. carries $479.0K in total debt against $148.1M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does Climb Bio, Inc. have?
- Climb Bio, Inc. holds $8.4M in cash and equivalents.
- Can Climb Bio, Inc. cover its short-term obligations?
- Its current ratio is 27.86 — current assets exceed current liabilities.
- Where does Climb Bio, Inc.'s balance sheet data come from?
- Every line is extracted from Climb Bio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.